Orthogonal Thinker Archives - Green Market Report

Debra BorchardtApril 27, 2020

The holding company known for its predilection towards psychedelics, Orthogonal Thinker, Inc. has closed on a total of $6 million in a series of oversubscribed seed rounds, which included investments from lead investors such as Republic Labs and Pay It Forward, along with other notable investors.
David Nikzad, Founder, Orthogonal Thinker said, The core focus of this fundraise is devoted to our wholly-owned subsidiary, EI. Ventures, and establishing its foundations as a leading player in the emerging psychedelic market. This is just the start of what’s to come for the market and EI. The next steps for EI will be devoted to our GMP and lab efforts.
Orthogonal said that intends to use the proceeds for Ei.Ventures. The company said in a statement that a large portion of the funds will be used to purchase a vertically integrated clinical lab and facility, which will be home to future clinical trials and compound formulations. Funding will also be used to begin Phase 1 Clinical Trials for Psilly, the company’s flagship, psychedelic product, which emphasizes the utilization of clean and natural formulas from whole plants versus biosynthetic methods as traditionally seen in the industry. The company recently filed a patent application for Psilly.
“Our investment into Orthogonal Thinker signals our conviction in the team and company. We admire what David Nikzad has built and believe in the company’s potential to become the leading brand in mental health and wellness,” said Christian Sullivan, Co-Founder of Republic Labs.

Orthogonal was launched in 2016 and the portfolio contains a variety of industries, including travel, food and beverage, and more. The brands Ei.Ventures and PsillyLife aim to foster mainstream acceptance for medical and legal adult-use psychedelics, encourage education in and democratization of the space, and modernize industry approach to the psychedelic space by focusing on effective and natural formulations.

“We have assembled a team of renowned scientists, policy leaders, legal experts, and business leaders to help with existing patents and further patenting our formulations. In the coming years, we believe that we will witness a worldwide paradigm shift regarding psilocybin and other psychoactive compounds, which will generate a multibillion-dollar industry. We will be at the forefront of the movement,” said Co-Founder and CEO, Jason Hobson.

Debra BorchardtApril 14, 2020

Biotech holding company Orthogonal Thinker, Inc. said that it has completed filing a provisional application for the Company’s flagship natural product, Psilly. The provisional application is a legal document filed in the United States Patent and Trademark Office (USPTO), that establishes an early filing date. It does not mature into an issued patent unless the applicant files a regular non-provisional patent application within one year.
“Filing this application allows us to move forward with expanding access to an improved version of psilocin that is not yet available on the market,” said Jason Hobson, CEO of Orthogonal. “This provides us further opportunity to strengthen relationships with organizations across the world who are on the forefront of psychedelic research as we continue to seek partners aligned with our mission to provide holistic wellness solutions. We look forward to sharing our cutting-edge technology to further therapeutic and medical innovations in healthcare. ”
Psilly is Othogonal’s proprietary psilocybin product. The company says that Psilly differs from other psilocybin products in development as it consists of a proprietary formula that uses natural, rather than biosynthetic, alkaloids. According to Wikipedia, alkaloids are produced by a large variety of organisms including bacteria, fungi, plants, and animals. Alkaloids possess psychotropic effects like psilocin and stimulant effects like caffeine.  Although alkaloids act on a diversity of metabolic systems in humans and other animals, they almost uniformly evoke a bitter taste.
The company said that some of the more than $5 million in total seed capital that the company recently raised were allocated to pursue the development and intellectual property protection on Psilly. PsillyLife is the Orthogonal’s lifestyle brand and was conceived to promote education and awareness surrounding the benefits of psilocybin to a worldwide audience.
Potential Patient Population
According to the Centers for Disease Control and Prevention (CDC), antidepressant use in the U.S. continues to grow. Nearly eight percent of the U.S. population took antidepressants between 1999–2002. Between 2011–2014, that number increased to almost 13% of the U.S. public. The global antidepressant and anti-anxiety drugs market is estimated to have reached $12.16bn in 2018. In 2018, the SSRIs segment held 26% of the global antidepressant and anti-anxiety drugs market.

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


We respect your privacy. See our privacy policy.

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

@GreenMarketRpt – 6 hours

Super excited to announce we set a date for our Tech Summit. It will be Sept 8, 2022 in San Francisco. Creating the…

@GreenMarketRpt – 7 hours

Medical Mushrooms Leave No Room For the Magic

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.


We respect your privacy. See our privacy policy.